# Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

> **NCT01081132** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 314 (actual)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Extended-release Guanfacine Hydrochloride
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01081132
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-19
- **Primary completion:** 2013-05-16
- **Final completion:** 2013-05-16
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2021-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081132, "Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01081132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*